What is anti-MIgG(Fc)-N-DM1 ADC?

This ADC consists of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. DM1 is a cytotoxic agent that targets tubulins, disrupting microtubule dynamics, and ultimately causing cell death.

How can anti-MIgG(Fc)-N-DM1 ADC be used to assess the efficacy of different Fc receptors in mediating ADC activity?

Researchers can use this ADC to compare how different Fc receptor variants on target cells influence the internalization and cytotoxicity of the ADC. This can help in identifying the most effective Fc receptor subtypes for targeted ADC therapies.

Can anti-MIgG(Fc)-N-DM1 ADC be utilized in high-throughput screening of cancer cell lines?

Yes, this ADC can be used in high-throughput screening to evaluate its cytotoxic effects across a wide range of cancer cell lines, particularly those expressing mouse IgG Fc receptors. This screening can identify potential cancer types that are more susceptible to this ADC treatment.

How can the internalization rate of anti-MIgG(Fc)-N-DM1 ADC be quantified?

The internalization rate can be quantified using fluorescence-tagged ADCs observed under a fluorescence microscope or quantified via flow cytometry. These methods can provide real-time data on the rate at which the ADC is taken up by the cells.

What experimental controls should be included when studying the anti-MIgG(Fc)-N-DM1 ADC's mechanism of action?

Controls should include cells that do not express mouse IgG Fc receptors to demonstrate specificity and an ADC lacking the cytotoxic payload (DM1) to confirm that observed effects are due to the cytotoxic agent and not merely ADC binding.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-MIgG(Fc)-N-DM1 ADC

anti-MIgG(Fc)-N-DM1 ADC (CAT#: ADC-AA-026)

This ADC product is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. The antibody portion is a secondary antibody and the drug portion, DM1, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-mouse IgG Fc specific polyclonal IgG antibody

Species Reactivity
Mouse

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-026. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Exceptional

Anti-MIgG(Fc)-N-DM1 ADC from Creative Biolabs delivers superb precision in targeting and disrupting tubulins, leading to effective cell death in our models.

Excellent

Creative Biolabs' Anti-MIgG(Fc)-N-DM1 ADC has significantly improved our mouse monoclonal antibody pre-screening process. Its efficacy and safety profile are top-notch.

Excellent

We've seen substantial advancements in our research using Anti-MIgG(Fc)-N-DM1 ADC. Its targeted action on microtubules is invaluable for understanding cellular dynamics.

Excellent

Anti-MIgG(Fc)-N-DM1 ADC offers excellent cytotoxic efficacy without the usual toxicity concerns, making it ideal for detailed cellular studies.

Excellent

Highly effective and safe, the Anti-MIgG(Fc)-N-DM1 ADC provides critical insights into antibody-dependent cellular cytotoxicity and other immunological effects.

Q: 1: What is anti-MIgG(Fc)-N-DM1 ADC?
A: This ADC consists of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. DM1 is a cytotoxic agent that targets tubulins, disrupting microtubule dynamics, and ultimately causing cell death.
Q: 2: How can anti-MIgG(Fc)-N-DM1 ADC be used to assess the efficacy of different Fc receptors in mediating ADC activity?
A: Researchers can use this ADC to compare how different Fc receptor variants on target cells influence the internalization and cytotoxicity of the ADC. This can help in identifying the most effective Fc receptor subtypes for targeted ADC therapies.
Q: 3: Can anti-MIgG(Fc)-N-DM1 ADC be utilized in high-throughput screening of cancer cell lines?
A: Yes, this ADC can be used in high-throughput screening to evaluate its cytotoxic effects across a wide range of cancer cell lines, particularly those expressing mouse IgG Fc receptors. This screening can identify potential cancer types that are more susceptible to this ADC treatment.
Q: 4: How can the internalization rate of anti-MIgG(Fc)-N-DM1 ADC be quantified?
A: The internalization rate can be quantified using fluorescence-tagged ADCs observed under a fluorescence microscope or quantified via flow cytometry. These methods can provide real-time data on the rate at which the ADC is taken up by the cells.
Q: 5: What experimental controls should be included when studying the anti-MIgG(Fc)-N-DM1 ADC's mechanism of action?
A: Controls should include cells that do not express mouse IgG Fc receptors to demonstrate specificity and an ADC lacking the cytotoxic payload (DM1) to confirm that observed effects are due to the cytotoxic agent and not merely ADC binding.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-056	Anti-MIgG-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-050	Protein G-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-W-495	Anti-EGFR-SMCC-DM1 ADC-4	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-582	Anti-ERBB2-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-015	anti-HIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-572	Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Creative Biolabs quality assurance certification